1. Rhein has been proved effective in treatment of experimental diabetic nephropathy (DN), one of the mechanism is the Inhibition of the hexosamine pathway.
2. Rhein has been shown to induce apoptosis in several cancer cell lines, and induces apoptosis in A-549 cells via a Ca2+ -dependent mitochondrial pathway.
3. Rhein has protective effect on liver injury and can inhibit liver flbrosis induced by CCl4/ethanol in rats,the mechanisms possibly contribute to its action of antioxidant and anti-inflammatory activity, also associated with its effect of inhibiting TGF-β1 and suppressing the activation of hepatic stellate cells.
1. Ruscogenin has been found to exert significant anti-inflammatory and anti-thrombotic activities; the possible mechanism of the anti-inflammatory activity is role of intercellular adhesion molecule-1 and nuclear factor-kappaB.
2. Ruscogenin significantly attenuates LPS-induced acute lung injury (ALI )via inhibiting expressions of TF and iNOS and NF-κB p65 activation, indicates that it as a potential therapeutic agent for ALI or sepsis.
3. Ruscogenin can protect the brain against ischemic damage caused by middle cerebral artery occlusion (MCAO), and this effect may be through downregulation of NF-κB-mediated inflammatory responses.
4. Ruscogenin inhibits activation of neutrophil through cPLA 2 , PAK, Akt, MAPKs, cAMP, and PKA signaling pathways.
5. Ruscogenin may attenuate high-fat diet (HFD)-induced steatohepatitis through downregulation of NF- κB-mediated inflammatory responses, reducing hepatic lipogenic gene expression, and upregulating proteins in β-oxidation pathway.
1. Lovastatin has a powerful inhibitory effect on HMG-CoA reductase.
2. Lovastatin has a potential application to treat PD via antioxidant effect.
3. Lovastatin promotes fibrosis and epithelial to mesenchymal transition, by regulating the production of CCN2 in human gingival fibroblasts.
4. Lovastatin has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy, at least in part, through suppression of glomerular expression of Transforming growth factor-beta (TGF-beta)1.
1. Morroniside would act as a regulator of hepatic inflammatory reactions and lipid metabolism in db/db mice.
2. Morroniside exhibits protective effects against diabetic renal damage and human umbilical vein endothelial cells , by inhibiting hyperglycemia and oxidative stress.
3. Morroniside can notably protect the brain from damage induced by focal cerebral ischemia which might be related to morroniside antioxidant and anti-apoptotic properties in the brain.
4. Morroniside and loganin have protective effects on rat mesangial cell proliferation exposed to advanced glycation end products by preventing oxidative stress.
5. Morroniside can improve microvascular functional integrity of the neurovascular unit after cerebral ischemia, it may offer a novel therapeutic approach for promoting microvascular integrity recovery and provide a thoroughly new direction for stroke therapy.
6. Morroniside can promote bone marrow mesenchymal stem cell proliferation in rats.
7. Morroniside can decrease the level of cycloxygenase(Cox) and it may be the mechanism of morroniside on inhibiting the platelet aggregation induced by ADP in rabbits.
1. Astilbin may act as an efficient therapeutic agent for arthritis like cyclosporine A but with less toxicity, its mechanism includes a selective suppression on lymphocyte functions via reducing MMP and NO production.
2. Astilbin can selectively facilitate the apoptosis of interleukin-2-dependentphytohemagglu- -tinin-activated Jurkat cells, the characteristic of astilbin may be of great significance for the treatment of a variety of immunologically related diseases.
3. Astilbin has insecticidal activity.
4. Astilbin shows strong antioxidant activity.
5. Astilbin alleviates contact hypersensitivity through a unique mechanism involving a negative cytokine regulation through stimulating IL-10, which is distinct from the immunosuppressant cyclosporin A.
6. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-α production and T lymphocyte adhesion.
7. Astilbin has antibacterial activity, the minimal inhibitory quantity (MIQs) of astilbin ranges from 50 to 100 microg.
8. Astilbin can exert an early renal protective role to diabetic nephropathy (DN), inhibit production of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF).
9. Astilbin might be due to block of the myocardial inflammatory cascade via the HMGB1-dependent NF-κB signaling pathway.
10. Astilbin possesses anti-inflammatory properties, could be a candidate drug for inflammatory bowel disease by mediating the regulatory functions of DCs.